Truvestments Capital’s Neurogene NGNE Stock Holding History

Truvestments Capital’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$927	Hold	46	–	–	﹤0.01%	1060
2025 Q4	$948	Hold	46	–	–	﹤0.01%	926
2025 Q3	$797	Hold	46	–	–	﹤0.01%	960
2025 Q2	$688	Hold	46	–	–	﹤0.01%	894
2025 Q1	$539	Hold	46	–	–	﹤0.01%	957
2024 Q4	$1.05K	Hold	46	–	–	﹤0.01%	917
2024 Q3	$1.93K	Buy	+46	New	+$1.78K	﹤0.01%	801
2024 Q2	–	Sell	-46	Closed	-$2.34K	–	514
2024 Q1	$2.34K	Hold	46	–	–	﹤0.01%	609
2023 Q4	$891	Hold	46	–	–	﹤0.01%	715
2023 Q3	$731	Hold	46	–	–	﹤0.01%	638
2023 Q2	$768	Hold	46	–	–	﹤0.01%	642
2023 Q1	$648	Hold	46	–	–	﹤0.01%	628
2022 Q4	$471	Hold	46	–	–	﹤0.01%	871
2022 Q3	$1K	Sell	46 -20	-30%	-$408	﹤0.01%	596
2022 Q2	$1K	Buy	+66	New	+$1.61K	﹤0.01%	612
2022 Q1	–	Sell	-66	Closed	-$6K	–	408
2021 Q4	$6K	Hold	66	–	–	﹤0.01%	458
2021 Q3	$10K	Hold	66	–	–	0.01%	379
2021 Q2	$12K	Hold	66	–	–	0.01%	370
2021 Q1	$16K	Hold	66	–	–	0.01%	395
2020 Q4	$18K	Buy	+66	New	+$16.1K	0.01%	376
2020 Q3	–	Sell	-66	Closed	-$21K	–	465
2020 Q2	$21K	Buy	+66	New	+$17.2K	0.02%	299
2019 Q4	–	Sell	-113	Closed	-$6K	–	423
2019 Q3	$6K	Sell	113 -12	-10%	-$732	﹤0.01%	553
2019 Q2	$6K	Hold	125	–	–	﹤0.01%	597
2019 Q1	$7K	Buy	+125	New	+$6.32K	0.01%	563
2018 Q3	$8K	Buy	+131	New	+$7.73K	﹤0.01%	679

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Truvestments Capital's NGNE Position: Q1 2026 in Review

Truvestments Capital held its Neurogene (NGNE) position steady in Q1 2026 at 46 shares worth $927. The position accounts for ﹤0.01% of the portfolio, ranked #1060.

Truvestments Capital first reported a position in NGNE in Q3 2018 and has held it in 25 quarters since. The position peaked at $21K in Q2 2020. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

Truvestments Capital held 46 shares of Neurogene worth $927 as of Q1 2026.
Truvestments Capital left its Neurogene share count unchanged in Q1 2026.
Neurogene made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #1060 holding.
Truvestments Capital first reported a position in Neurogene in Q3 2018 and has held it in 25 quarters since.
Truvestments Capital's Neurogene position peaked at $21K in Q2 2020.
96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.